advesya

Advesya aims to develop and commercialise CAR-T cell therapies focusing on haematology and oncology, targeting acute myeloid leukaemia (AML) based on a first-in-class approach with a high degree of tumour selectivity and an optimised safety profile.

Building B2
Industry Biotech
Research Topics cellular immunotherapy
Employees 7
Founding year 2000